SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026
Rhea-AI Summary
Sera Prognostics (Nasdaq: SERA) will report fourth quarter and fiscal year 2025 financial results on Wednesday, March 18, 2026, after market close.
The company will host a conference call and live webcast at 5:00 p.m. ET to discuss operational highlights, financial results and key topics. A press release with results will be distributed before the call. Live audio and an archived webcast will be available on the Investors page at www.sera.com for one year.
Positive
- None.
Negative
- None.
News Market Reaction – SERA
On the day this news was published, SERA declined 4.27%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SERA fell 5.38% while only one peer in the momentum scan (LUCD) moved, down 3.45%, and sector peers showed mixed moves, pointing to a stock-specific move rather than a sector-wide rotation.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 30 | Earnings call notice | Neutral | -2.1% | Announced Q3 2025 results date and post-close conference call logistics. |
| Jul 29 | Earnings call notice | Neutral | -1.0% | Scheduled Q2 2025 financial results release and investor call details. |
| Apr 24 | Earnings call notice | Neutral | -2.0% | Set Q1 2025 results timing and provided conference call access numbers. |
| Mar 11 | Earnings call notice | Neutral | +1.9% | Announced FY 2024 and Q4 2024 results date and webcast information. |
| Oct 28 | Earnings call notice | Neutral | +0.6% | Outlined Q3 2024 results release timing and related conference call. |
Similar conference-call scheduling headlines have historically produced small, mixed price moves, with an average move of -0.53% around such announcements.
This announcement continues Sera Prognostics’ pattern of pre-announcing earnings calls and webcasts, as seen for each quarter of fiscal 2024 and 2025. Prior "conferences,earnings" notices for Q1–Q3 2025 and FY 2024 all followed the same format: results released after market close, followed by a 5:00 p.m. ET call and a one-year webcast archive. Outside these notices, recent news highlighted PRIME study publication and clinical impact, plus Q3 2025 results featuring early commercialization and cash runway details.
Historical Comparison
Past 5 "conferences,earnings" notices around results dates saw an average move of -0.53%, indicating typically modest reactions to similar scheduling updates.
The company has consistently pre-announced conference calls for Q3 2024 through FY 2025, maintaining a recurring pattern of post-close results releases followed by 5:00 p.m. ET webcasts and year-long archives.
Market Pulse Summary
This announcement sets the timing for Sera Prognostics’ fourth quarter and fiscal year 2025 results and the accompanying 5:00 p.m. ET call and webcast. It continues a regular pattern of pre-announcing earnings dates, as seen throughout fiscal 2024–2025. Recent history includes PRIME study publication, Q3 2025 financial metrics, and multiple SEC filings, including Form 4 insider sales and a Schedule 13G/A showing a 9.2% passive holder. Investors may watch how FY 2025 results build on these prior milestones.
AI-generated analysis. Not financial advice.
Conference Call Details:
US domestic callers: (800) 836-8184
International callers: (646) 357-8785
Webcast Registration Link: https://app.webinar.net/rd0XDOVL85p
Live audio of the webcast will be available online from the Investors page of the Company's website at www.sera.com. The webcast will be archived on the Investors page and will be available for one year.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2025 March of Dimes Report Card shows that, for the fourth consecutive year, the United States earned a D+ grade for preterm birth, making the longest stretch of the lowest grade in Report Card history. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM® Test is ordered by a medical professional.
Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the date and time and content of the Company's quarterly earnings release and conference call; availability of the live audio of the conference call on the Company's website; and the Company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Investor Contact
Jennifer Zibuda, Head of Investor Relations
jzibuda@sera.com
+1 (801) 396-8043
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-announces-conference-call-and-webcast-of-fourth-quarter-and-fiscal-year-2025-financial-results-on-march-18-2026-302702607.html
SOURCE Sera Prognostics, Inc.
FAQ
When will SERA report Q4 and fiscal 2025 results and what time is the conference call?
How can investors access the SERA March 18, 2026 webcast and call details?
Will the SERA webcast for March 18, 2026 be available after the live event?
What topics will SERA cover during the March 18, 2026 conference call?
What phone numbers should U.S. and international investors use to join the SERA earnings call?
